Mayne Pharma Group Ltd.ASX: MYX

MYX settles US patent litigation re Imvexxy with Teva USA

· Issued by Mayne Pharma Group Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Mayne Pharma Group Ltd. has announced the settlement of US patent litigation regarding IMVEXXY with Teva Pharmaceuticals USA, resolving ongoing Paragraph IV litigation related to FDA Orange Book patents. This agreement eliminates all outstanding Paragraph IV litigation matters for IMVEXXY, allowing Mayne Pharma to focus on its long-term planning for the product.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/myx-settles-us-patent-litigation-re-imvexxy-with-teva-usa

Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call

Release

ASX Announcement MAYNE PHARMA SETTLES US PATENT LITIGATION RELATING TO IMVEXXY® WITH TEVA PHARMACEUTICALS USA Key Points: • Settlement reached with Teva Pharmaceuticals USA resolving Paragraph IV litigation concerning IMVEXXY® FDA Orange Book patents • Settlement includes an agreed...

Mayne Pharma Group Ltd. on 6ix

Story so far

Earlier from Mayne Pharma

All Mayne Pharma news releases